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Predictive validity and immune cell involvement in the pathogenesis 
of piroxicam-accelerated colitis in interleukin-10 knock out mice. 
Introduction  
 Piroxicam-accelerated colitis (PAC) in 
interleukin-10 knock out (IL-10 k.o.) mice 
combines a dysregulated immune response 
against the gut microbiota with a decreased 
mucosal integrity (Berg et al. Gastroent, 2002; 
Holgersen et al. JCC, 2013) 
 
 The PAC IL-10 k.o. mouse is an useful in vivo 
model of inflammatory bowel disease (IBD). 
However, the predictive validity and pathogenic 
mechanisms of the model have not been 
thoroughly investigated.  
 
 The aim of this study was: 
1. To qualify the PAC IL-10 k.o. model by 
examining the efficacy of IBD reference 
drugs on colonic inflammation. 
2. To elucidate the pathophysiologic role of 
IBD-relevant immune cells in the PAC IL-10 
k.o. model by depletion of specific immune 
cell subsets. 
 
Methods  
 C57BL/6 IL-10 k.o. mice received piroxicam in 
the chow, throughout the study.  
 
 Mice were treated prophylactically with anti-IL-
12/23p40 monoclonal antibodies (mAb), anti-
TNFα mAb, cyclosporine A (CsA) or oral 
prednisolone. n = 8-12 mice per group. 
 
 CD4+ cells, CD8+ cells and macrophages were 
depleted prophylactically by treatment with anti-
CD4 mAb, anti-CD8 mAb and clodronate-
encapsulted liposomes, respectively. T cell 
receptor co-stimulation was blocked by CTLA4-
Ig (Orencia). n = 10-14 mice per group. 
 
 Histological analysis, cytokine profiling ELISAs 
and calprotectin immunohistochemistry were 
performed on colon tissue from studies showing 
treatment effect in the PAC IL-10 k.o. model. 
 
 
Conclusions 
  
 Reference drugs with known efficacy in severe 
IBD were efficacious in the PAC IL-10 k.o. 
model. 
 
 The ameliorative drugs reduced the colonic 
levels of IFNγ, IL-17A, MPO and calprotectin, 
which indicates that these cytokines, and/or the 
cells that secrete them, play an important role 
in disease development. 
 
 CD8+ cells seem to protect against disease in 
the PAC IL-10 k.o. model. In contrast, our data 
indicate that macrophages are a main driver of 
the colitis, whereas CD4+ cells are not.   
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Figure 1. Anti-IL-12/23p40 mAb, anti-TNFα mAb and cyclosporine A (CsA) treatment prevented weight loss and attenuated colonic pathology of 
PAC IL-10 k.o. mice. W: L = weight: length. *p<0.05,**p<0.01,***p<0.001. 
   
Figure 3. Colon cytokine profile of PAC IL-10 k.o. mice treated with the specified drugs. 
*p<0.05,**p<0.01,***p<0.001. 
 
Figure 4. The colonic calprotectin density was correlated with disease activity of PAC IL-10 k.o. mice. 
Anti-IL-12/23p40 mAb and CsA treatment significantly decreased the level of calprotectin in the colon.  
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Figure 2. Depletion of CD8+ cells tended to increase mortality, whereas depletion of CD4+ cells or 
treatment with CTLA4-Ig (10 mg/kg) had no effect on disease progression. Depletion of macrophages 
induced  body weight loss; nevertheless it was associated with significantly reduced colonic 
pathology. *p<0.05,**p<0.01,***p<0.001. 
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